OptiNose

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OptiNose prioritizes XHANCE launch for sinusitis, eyes growth opportunities

OptiNose is focusing on profitability and preparing for the launch of XHANCE for chronic sinusitis, anticipating improved financial performance in 2023.
The company's strategic initiatives include exploring commercial partnerships, optimizing expenses, and evaluating potential sale options, indicating a proactive approach to growth.
While facing challenges in revenue generation and prescription volumes, OptiNose is leveraging strengths in financial stability, market reach, and growth opportunities.

OptiNose reports steady Q1 performance amidst revenue challenges and growth opportunities

OptiNose's Q1 2023 performance showed steady prescription demand and a strategic focus on profitability and growth.
While facing challenges like revenue decline and sales force impact, the company is poised for opportunities in market expansion and successful product launches.
Overall, OptiNose remains optimistic about meeting expectations and future approval, positioning itself for continued success in the pharmaceutical market.

OptiNose reports steady Q2 performance, eyes growth with new indications

OptiNose's Q2 2023 performance showed stable prescription demand and a strategic focus on the potential launch of a chronic sinusitis treatment in 2024.
While facing challenges like slightly lower net revenue and upcoming operating expenses, the company is well-positioned for growth opportunities.
With raised revenue guidance, a clear operating strategy, and ongoing FDA review, OptiNose is poised for potential revenue expansion and market growth.

OptiNose reports stable Q3 revenue, eyes growth through XHANCE launch

OptiNose's Q3 2023 performance showed stability in revenue and improved cost efficiency.
While facing challenges in prescription numbers, the company is strategically positioned for growth.
Opportunities lie in potential market expansion through new indications and partnerships.

OptiNose reports strategic growth in Q4 2023, eyes XHANCE approval

OptiNose's performance in Q4 2023 showcased progress in key areas, with a strategic focus on growth and efficiency. The company's financials reflected a reduction in expenses and a stable product demand, positioning it well for potential XHANCE approval and revenue expansion.

OptiNose reports strong Q1 performance and outlines growth strategies

OptiNose's Q1 2024 performance reflects growth in XHANCE net revenue and a strengthened financial position.
The company's strategic focus on chronic sinusitis launch and improved base business fundamentals bode well for future growth.
Opportunities lie in expanding sales efforts, international partnerships, and new product development for sustained value creation.

OptiNose reports Q3 revenue growth, adjusts full-year guidance

OptiNose's Q3 performance showed revenue growth and strategic adjustments.
While challenges like conservative guidance were raised, opportunities for growth exist.
Management's focus on execution and communication bodes well for future prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

YARDLEY, Pa., Oct.  04, 2019  (GLOBE NEWSWIRE) --   Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported the creation of a new role of Vice President, Business Development and appointment of Michael Richardson into the new position. In this role, Michael will be responsible for identifying, evaluating, and executing on business development opportunities that support the overall corporate strategy.

Optinose Appoints Michael Richardson to New Position of Vice President, Business Development

YARDLEY, Pa., Sept.  27, 2019  (GLOBE NEWSWIRE) --  Optinose  (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2019 Cantor Global Healthcare Conference on October 2, 2019, at 11:15 a.m. ET.

Optinose to Present at the 2019 Cantor Global Healthcare Conference

YARDLEY, Pa., Sept.  26, 2019  (GLOBE NEWSWIRE) --  OptiNose , Inc.  (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the signing of an agreement between its Norway-based subsidiary OptiNose AS and Currax Pharmaceuticals LLC (Currax) which grants Currax the exclusive rights to certain Optinose intellectual property for the purpose of marketing ONZETRA® XSAIL® (sumatriptan nasal powder) in the United States, Canada, and Mexico.

OptiNose Announces License Agreement Related to ONZETRA XSAIL

Company reiterates guidance for XHANCE net revenues for 2019 to be in the range of $29 - $34 million Company reiterates guidance for XHANCE net revenues for 2019 to be in the range of $29 - $34 million

Optinose Announces Departure of Chief Commercial Officer

YARDLEY, Pa., Sept.  12, 2019  (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported that it has entered into a note purchase agreement for up to $150 million of senior secured notes with funds managed by Pharmakon Advisors, LP (“Pharmakon”), the investment manager of the BioPharma Credit funds.

Optinose Announces $150 Million Debt Financing from Pharmakon

OptiNose Inc’s (NASDAQ: OPTN) XHANCE nasal spray continued to exhibit encouraging trends in the second quarter, suggesting that the company's launch is progressing on track, according to RBC Capital Markets.

OptiNose's Q2 Results Reflect Strong Underlying Trends, RBC Says

OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2019 Results - Earnings Call Transcript

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate OptiNose (OPTN) to Report a Decline in Earnings: What to Look Out for

OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2019 Results - Earnings Call Transcript

OptiNose Inc. has introduced a new and simplified co-pay assistance program that's led to good script performance, according to Cantor Fitzgerald.

OptiNose Analysts Projects Prescription Growth In 2019, Beyond

News for OptiNose Stock (OPTN)